Fibroblast growth factor 23 and acute kidney injury

Javier A. Neyra, Orson W Moe, Ming C Hu

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Fibroblast growth factor 23 (FGF23), which is produced in bone, participates in the maintenance of phosphate metabolism and can serve as a biomarker for adverse cardiovascular outcomes in patients with chronic kidney disease and end-stage renal disease. Circulating FGF23 rapidly increases after acute kidney injury (AKI), preceding other known markers such as neutrophil gelatinase-associated lipocalin and serum creatinine. The increase in FGF23 in AKI appears to be independent of parathyroid hormone, vitamin D signaling pathways, and dietary phosphate. The potential mechanisms include: (1) increased production of FGF23 in the bone by yet-to-be-identified factors; (2) ectopic production of FGF23 by injured renal tubules; and (3) decreased renal clearance of circulating FGF23. Circulating FGF23 determined by intact FGF23 enzyme-linked immunosorbent assay (ELISA) is a more reliable biomarker of AKI than FGF23 C-terminal ELISA (a mixed readout of C-terminal fragment and intact FGF23). Given that FGF23 can be ectopically expressed in differentiated renal tubules and iron modulates FGF23 metabolism, an effect of iron on FGF23 expression in renal tubules is conceivable but remains to be confirmed. More clinical and experimental studies are required to validate the use of circulating FGF23 as a biomarker for the early identification of AKI and prediction of short- and long-term adverse outcomes post-AKI. More importantly, the biologic effect of increased FGF23 in AKI needs to be defined.

Original languageEnglish (US)
Pages (from-to)1909-1918
Number of pages10
JournalPediatric Nephrology
Volume30
Issue number11
DOIs
StatePublished - Dec 6 2014

Fingerprint

Acute Kidney Injury
Kidney
Biomarkers
fibroblast growth factor 23
Iron
Enzyme-Linked Immunosorbent Assay
Phosphates
Bone and Bones
Parathyroid Hormone
Chronic Renal Insufficiency
Vitamin D
Chronic Kidney Failure
Creatinine
Maintenance

Keywords

  • Acute kidney injury
  • Bone
  • FGF23
  • Iron
  • Klotho

ASJC Scopus subject areas

  • Nephrology
  • Pediatrics, Perinatology, and Child Health

Cite this

Fibroblast growth factor 23 and acute kidney injury. / Neyra, Javier A.; Moe, Orson W; Hu, Ming C.

In: Pediatric Nephrology, Vol. 30, No. 11, 06.12.2014, p. 1909-1918.

Research output: Contribution to journalArticle

Neyra, Javier A. ; Moe, Orson W ; Hu, Ming C. / Fibroblast growth factor 23 and acute kidney injury. In: Pediatric Nephrology. 2014 ; Vol. 30, No. 11. pp. 1909-1918.
@article{504f83bb50f846098fc9937835afc8f3,
title = "Fibroblast growth factor 23 and acute kidney injury",
abstract = "Fibroblast growth factor 23 (FGF23), which is produced in bone, participates in the maintenance of phosphate metabolism and can serve as a biomarker for adverse cardiovascular outcomes in patients with chronic kidney disease and end-stage renal disease. Circulating FGF23 rapidly increases after acute kidney injury (AKI), preceding other known markers such as neutrophil gelatinase-associated lipocalin and serum creatinine. The increase in FGF23 in AKI appears to be independent of parathyroid hormone, vitamin D signaling pathways, and dietary phosphate. The potential mechanisms include: (1) increased production of FGF23 in the bone by yet-to-be-identified factors; (2) ectopic production of FGF23 by injured renal tubules; and (3) decreased renal clearance of circulating FGF23. Circulating FGF23 determined by intact FGF23 enzyme-linked immunosorbent assay (ELISA) is a more reliable biomarker of AKI than FGF23 C-terminal ELISA (a mixed readout of C-terminal fragment and intact FGF23). Given that FGF23 can be ectopically expressed in differentiated renal tubules and iron modulates FGF23 metabolism, an effect of iron on FGF23 expression in renal tubules is conceivable but remains to be confirmed. More clinical and experimental studies are required to validate the use of circulating FGF23 as a biomarker for the early identification of AKI and prediction of short- and long-term adverse outcomes post-AKI. More importantly, the biologic effect of increased FGF23 in AKI needs to be defined.",
keywords = "Acute kidney injury, Bone, FGF23, Iron, Klotho",
author = "Neyra, {Javier A.} and Moe, {Orson W} and Hu, {Ming C}",
year = "2014",
month = "12",
day = "6",
doi = "10.1007/s00467-014-3006-1",
language = "English (US)",
volume = "30",
pages = "1909--1918",
journal = "Pediatric Nephrology",
issn = "0931-041X",
publisher = "Springer Verlag",
number = "11",

}

TY - JOUR

T1 - Fibroblast growth factor 23 and acute kidney injury

AU - Neyra, Javier A.

AU - Moe, Orson W

AU - Hu, Ming C

PY - 2014/12/6

Y1 - 2014/12/6

N2 - Fibroblast growth factor 23 (FGF23), which is produced in bone, participates in the maintenance of phosphate metabolism and can serve as a biomarker for adverse cardiovascular outcomes in patients with chronic kidney disease and end-stage renal disease. Circulating FGF23 rapidly increases after acute kidney injury (AKI), preceding other known markers such as neutrophil gelatinase-associated lipocalin and serum creatinine. The increase in FGF23 in AKI appears to be independent of parathyroid hormone, vitamin D signaling pathways, and dietary phosphate. The potential mechanisms include: (1) increased production of FGF23 in the bone by yet-to-be-identified factors; (2) ectopic production of FGF23 by injured renal tubules; and (3) decreased renal clearance of circulating FGF23. Circulating FGF23 determined by intact FGF23 enzyme-linked immunosorbent assay (ELISA) is a more reliable biomarker of AKI than FGF23 C-terminal ELISA (a mixed readout of C-terminal fragment and intact FGF23). Given that FGF23 can be ectopically expressed in differentiated renal tubules and iron modulates FGF23 metabolism, an effect of iron on FGF23 expression in renal tubules is conceivable but remains to be confirmed. More clinical and experimental studies are required to validate the use of circulating FGF23 as a biomarker for the early identification of AKI and prediction of short- and long-term adverse outcomes post-AKI. More importantly, the biologic effect of increased FGF23 in AKI needs to be defined.

AB - Fibroblast growth factor 23 (FGF23), which is produced in bone, participates in the maintenance of phosphate metabolism and can serve as a biomarker for adverse cardiovascular outcomes in patients with chronic kidney disease and end-stage renal disease. Circulating FGF23 rapidly increases after acute kidney injury (AKI), preceding other known markers such as neutrophil gelatinase-associated lipocalin and serum creatinine. The increase in FGF23 in AKI appears to be independent of parathyroid hormone, vitamin D signaling pathways, and dietary phosphate. The potential mechanisms include: (1) increased production of FGF23 in the bone by yet-to-be-identified factors; (2) ectopic production of FGF23 by injured renal tubules; and (3) decreased renal clearance of circulating FGF23. Circulating FGF23 determined by intact FGF23 enzyme-linked immunosorbent assay (ELISA) is a more reliable biomarker of AKI than FGF23 C-terminal ELISA (a mixed readout of C-terminal fragment and intact FGF23). Given that FGF23 can be ectopically expressed in differentiated renal tubules and iron modulates FGF23 metabolism, an effect of iron on FGF23 expression in renal tubules is conceivable but remains to be confirmed. More clinical and experimental studies are required to validate the use of circulating FGF23 as a biomarker for the early identification of AKI and prediction of short- and long-term adverse outcomes post-AKI. More importantly, the biologic effect of increased FGF23 in AKI needs to be defined.

KW - Acute kidney injury

KW - Bone

KW - FGF23

KW - Iron

KW - Klotho

UR - http://www.scopus.com/inward/record.url?scp=84942374262&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84942374262&partnerID=8YFLogxK

U2 - 10.1007/s00467-014-3006-1

DO - 10.1007/s00467-014-3006-1

M3 - Article

C2 - 25480729

AN - SCOPUS:84942374262

VL - 30

SP - 1909

EP - 1918

JO - Pediatric Nephrology

JF - Pediatric Nephrology

SN - 0931-041X

IS - 11

ER -